Compstatin Analogues Alkylene Bridge Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current complement inhibitors, such as compstatin analogues, face challenges in optimizing activity, pharmacokinetic properties like half-life, and physicochemical stability to effectively inhibit excessive or inappropriate activation of the complement cascade, particularly in autoimmune and inflammatory diseases.
Innovation Solution
Development of compstatin analogues with an alkylene bridge between sulphur atoms of cysteine residues instead of disulphide bonds, enhancing stability and binding affinity to C3 protein, and introducing modifications like isoleucine at position 3 and lysine or serine at position 11, which improve solubility and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If a disulphide bond is used in compstatin, then the molecule has structural stability, but the physicochemical stability and solubility are insufficient
Solution Approach 1:
The patent changes the chemical parameter of the linkage between cysteine residues from a disulphide bond to an alkylene bridge (specifically methylene thioacetal linkage). This parameter change improves physicochemical stability and solubility while maintaining structural integrity necessary for C3 binding.
Solution Approach 2:
The patent creates a hybrid structure by combining the alkylene bridge (non-covalent-like stability) with the cysteine residue framework, forming a composite linkage that exhibits both improved physicochemical properties and maintained biological activity. The methylene thioacetal linkage acts as a composite connector that preserves the cyclic structure while enhancing stability.
2Duration of action of stationary object
If the compstatin structure is modified to improve stability, then pharmacokinetic properties improve, but binding affinity to C3 may be reduced
Solution Approach 1:
The modification is localized specifically to the linkage between cysteine residues at positions 2 and 12, leaving the rest of the compstatin structure unchanged. This local modification approach allows improvement of pharmacokinetic properties (half-life) while preserving the critical binding interface with C3 protein.
Solution Approach 2:
The alkylene bridge provides beforehand cushioning by creating a more stable structural framework that resists degradation in vivo. This pre-established stability cushion protects the molecule from premature breakdown, extending half-life without compromising the binding interface.
3Reliability
If compstatin analogues are developed with improved stability, then therapeutic potential increases, but structural complexity increases
Solution Approach 1:
The patent extracts the disulphide bond component and replaces it with a simpler alkylene bridge structure. This extraction of the problematic disulphide linkage and substitution with a more stable but structurally simpler bridge reduces molecular complexity while enhancing therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compstatin analogues with an alkylene bridge demonstrate improved stability, solubility, and binding efficacy, effectively inhibiting complement activation, potentially offering enhanced therapeutic benefits for autoimmune and inflammatory diseases.
Implementation Method 1
Introducing such an alkylene binding (bridge) between cysteine residues in positions 2 and 12, for example through use of a thioacetal linkage (e.g. methylene thioacetal) thus improves the overall physicochemical properties for compstatin analogues.
Implementation Method 2
These compstatin analogues may additionally possess improved binding and complement-inhibiting activity as compared to the 13 amino acid compstatin peptide
Implementation Method 3
During the same simulations we observe an aliphatic-pi stacking interaction between the aliphatic beta-carbon of cysteine 12 and the aromatic sidechain of tryptophan 4.
Data Source
AI summary
Compstatin analogues having improved physicochemical properties, such as increased stability and/or solubility as compared to the 13 amino acid compstatin peptide are described, in particular compstatin analogues that additionally possess useful binding and complement-inhibiting activity. These analogues have an alkylene bridge between sulphur atoms of cysteine residues and include variants with an isoleucine residue at position 3 in place of the wild type valine residue, which provides compstatin peptides with improved binding and complement-inhibiting activity and also enables the introduction of other modifications, for example modifications that are capable of increasing stability, such as the introduction of lysine or serine at position 11.